Compare Amgen, Inc. (AMGN) vs Centrus Energy Corp (LEU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Centrus Energy Corp — how do they compare? Amgen, Inc. trades at $416.04 (market cap $224.14B), while Centrus Energy Corp trades at $185.4 (market cap $3.77B). The key difference: Amgen, Inc. is far larger — about 59.5× Centrus Energy Corp's market cap, and Amgen, Inc. pays a 2.43% dividend while Centrus Energy Corp pays none. Which is the better fit depends on your goals.
| AMGN | LEU | |
|---|---|---|
Market Cap | $224.14B | $3.77B |
Sector | Health | Energy |
52-Week High | $417.20 | $436.00 |
52-Week Low | $271.18 | $146.61 |
Enterprise Value | $267.45B | $3.08B |
Dividend Yield | 2.43% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $417.44, up 0.06% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 results, beating EPS estimates and raising full-year guidance, driven by robust product growth. Revenue reached $36.75B in 2025 with a net income margin of 22.95%, though high debt levels remain a focus.
Outlook is positive given earnings momentum and raised guidance, but risks include competitive pressures and a data breach investigation. Analyst consensus is Buy with a $394.69 price target, suggesting near-term consolidation after recent gains. The stock's valuation multiples are elevated relative to historical levels.
Centrus Energy (LEU) trades at $186.93, down 1.27% on the day, with a bullish technical signal from moving averages. The company reported mixed Q2 2026 results, beating earnings estimates but showing margin compression. LEU maintains a strong $4.5 billion backlog and secured significant DOE funding, positioning it as a key player in the domestic nuclear fuel supply chain. Valuation metrics appear elevated with a P/E of 68.23 and P/S of 8.89, reflecting growth expectations in the nuclear energy sector.
The outlook remains positive given government support for nuclear energy and Centrus's strategic position in HALEU production. However, investors face risks from execution challenges, cost pressures, and the capital-intensive nature of enrichment facility expansion. Analyst consensus leans bullish with a $228.50 price target, though the stock's premium valuation requires careful monitoring of operational milestones and margin trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Centrus Energy Corp
Centrus Energy is a leading supplier of nuclear fuel and services for the global power industry. It specializes in supplying low-enriched uranium and developing next-generation fuels for advanced nuclear reactors.
Read more on LEU →
